SecBot SecBot
SECBOTREPLAY Home › Report › CLDX

CLDX · Celldex presented positive Phase 1 data for CDX-622, a bispecific…

Celldex Therapeutics, Inc. · PRESS-RELEASE filed Jun 14, 2026 at 05:15 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 14, 2026 at 05:15 ET

Celldex presented positive Phase 1 data for CDX-622, a bispecific antibody targeting SCF and TSLP, at EAACI. The drug showed rapid, durable, dose-dependent reductions in serum tryptase (indicating mast cell depletion) and was well-tolerated at all doses with no dose-limiting toxicities or related serious adverse events. This validates a novel mechanism (neutralizing soluble SCF to selectively inhibit KIT signaling in mast cells) and supports advancing into Phase 1b proof-of-concept studies in asthma, allergic rhinitis, and food allergy.

  • CDX-622 induced rapid, profound, dose-dependent, and durable reductions in serum tryptase, indicating tissue mast cell depletion.
  • No dose-limiting toxicities or related serious adverse events; most common adverse event was Grade 1 headache.
  • No changes in hair/skin pigmentation or meaningful impact on hematologic parameters, addressing a key safety concern for KIT-targeting therapies.
  • CDX-622 exhibited monoclonal antibody-like pharmacokinetics with extended half-life and good subcutaneous bioavailability.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access